OnCo

VIP

Checked 2026-09-09

Poor-risk germ cell tumours first line when bleomycin is contraindicated, and salvage after BEP

Also called VIP (etoposide, ifosfamide, cisplatin).

One cycle

every 21 days × 4 · about 12 weeks in total
178141521Etoposide: 75 mg/m², IntravenousEtoposideIfosfamide: 1,200 mg/m² with mesna, IntravenousIfosfamideCisplatin: 20 mg/m², IntravenousCisplatin
21-day cycle × 4 (about 12 weeks)Intravenous

Components

DrugDoseRouteDays
Etoposide
Topoisomerase II inhibitor (podophyllotoxin derivative)
75 mg/m²IVD1-5
Ifosfamide
Cytotoxic chemotherapy (alkylating agent)
1,200 mg/m² with mesnaIVD1-5
Cisplatin
Cytotoxic chemotherapy (platinum)
20 mg/m²IVD1-5
Cycles
4
21-day cycle
Emetogenicity
High (>90%)
G-CSF
Recommended

Notes

  • Equivalent to BEP in poor-risk disease with more myelosuppression but no bleomycin lung toxicity.

Used in

Source

Nichols (ECOG/SWOG), JCO 1998: VIP versus BEP in advanced disseminated germ cell tumours

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers